Abstract: Recombinantly produced interleukin-2 exhibits human IL-2 activity, has a molecular weight of about 15,000 daltons, is activity stable at a pH of 2-9 and is resistant to elevated temperatures. The recombinant IL-2 has the principal biological activity of human IL-2, promotion of proliferation of cytotoxic T lymphocytes.
Type:
Grant
Filed:
July 26, 1993
Date of Patent:
March 21, 1995
Assignees:
Ajinomoto Co., Inc., Japanese Foundation For Cancer Research
Abstract: Signal sequences based on LamB have been constructed. These signal sequences facilitate both the synthesis and secretion of neurotrophins in E. coli.
Abstract: Novel fusions of a GPI signal domain and a polypeptide heterologous to the GPI signal domain donor polypeptide are provided for industrial use. Therapeutic administration of the GPI-linked product of the fusions enables the targeting of biological activity to cell membrane surfaces.
Abstract: A novel mammalian cytokine, IL-11, and processes for producing it are disclosed. IL-11 may be used in pharmaceutical preparations for stimulating and/or enhancing cells involved in the immune response and cells involved in the proper functioning of the hematopoietic system.
Type:
Grant
Filed:
February 12, 1993
Date of Patent:
December 6, 1994
Assignee:
Genetics Institute, Inc. - Legal Affairs
Inventors:
Frances K. Bennett, Stephen R. Paul, Yu-Chung Yang
Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1 (murine flk-2), FIG. 2 (human flk-2) and FIG. 3 (murine flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1 (murine flk-2); FIG. 2 (human flk-2) and FIG. 3; ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation and/or differentiation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.
Abstract: Disclosed is recombinant penetrin polypeptide. Also disclosed is nucleic acid encoding penetrin, recombinant cells and plasmids encoding penetrin, antibodies directed against penetrin and various uses for penetrin and antibodies directed against penetrin.
Type:
Grant
Filed:
August 6, 1993
Date of Patent:
June 21, 1994
Assignee:
New England Medical Center Hospitals, Inc.
Inventors:
Miercio E. A. Pereira, Eduardo Ortega-Barria
Abstract: This invention provides for improved means to produce binding specific proteins using concatamers of semi-randomly generated oligonucleotides inserted into genes encoding the external domains of bacterial outer membrane proteins. The genes are induced to express and the bacteria are then screened for the ability to bind to predetermined compositions. Those clones carrying the desired binding protein are isolated, cultured and the protein purified. Increased avidity of the binding specific proteins are achieved by reisolating the oligonucleotides which conferred binding affinity and mixing them with new semi-randomly generated oligonucleotides to generate a population enriched for oligonucleotides that had previously conferred to bacteria the desired binding affinity.
Type:
Grant
Filed:
April 15, 1992
Date of Patent:
May 31, 1994
Assignee:
The United States of America as represented by Department of Health and Human Services
Abstract: The invention concerns antigens from the intraerythrocytic phase of Plasmodium falciparum, namely: a protein of 50 kDa with an isoelectric point of 5.5 and a protein of 65 kDa separated by electrophoresis in reducing conditions into two polypeptides of 47 and 18 kDa, both appearing in the serum of patients infected by Plasmodium falciparum or in the culture medium of this microorganism during its intraerythrocytic phase, as well as a protein of 126 kDa synthesized during the nuclear multiplication phase during schizogony and localized on the periphery of the schizonts at the parasitophore vacuole level, precursor of the 50 kDa and 65 kDa proteins. Application of these proteins in the preparation of vaccines against malaria, and monoclonal antibodies corresponding to the assay of the antibodies of an immunized subject and assay of the antigens according to the invention during an attack of malaria.
Type:
Grant
Filed:
February 26, 1991
Date of Patent:
February 15, 1994
Inventors:
Alain Vernes, Francois J. Dubrometz, Bernard Fortier, Patrick Deplace
Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1(flk-2) and FIG. 2 (flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1(flk-2) and FIG. 2 (flk-1); ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.
Abstract: A novel DNA sequence is disclosed which encodes a protein associated with many human cancers. This protein is designated as metallopanstimulin-1 (MPS-1) since (1) it is associated with metal ions, particularly zinc; (2) it has been detected in numerous different types of cells; (3) it is associated with rapid cell proliferation. The MPS-1 mRNA and its encoded protein are expressed in normal cells to a much lesser degree than in premalignant or malignant tumor cells, and they are present at very low levels in senescent cells compared to young healthy cells. The DNA sequence and the protein can be used in diagnostic methods such as detection of malignant cells associated with several types of tumors. Thus, this invention discloses a method for determining the presence of certain types of malignant conditions in patients. The MPS-1 cDNA sequence has been inserted into convenient vectors, and a culture of E.
Abstract: Disclosed is recombinant penetrin polypeptide. Also disclosed is nucleic acid encoding penetrin, recombinant cells and plasmids encoding penetrin, antibodies directed against penetrin and various uses for penetrin and antibodies directed against penetrin.
Type:
Grant
Filed:
October 17, 1991
Date of Patent:
August 10, 1993
Assignee:
New England Medical Center Hospitals, Inc.
Inventors:
Miercio E. A. Pereira, Eduardo Ortega-Barria